Bevacizumab for the Treatment of Corneal Neovascularization

Inclusion Criteria: * Significant unilateral or bilateral corneal neovascularization that extending over the limbus at least 2mm. * The underlying etiologies that caused corneal neovascularization included post penetrating keratoplasty (PKP), ocular surface reconstruction , trauma, infectious or non-infectious corneal ulcer. * Corneal neovascularization induced lipid keratopathy, corneal edema, or irregular corneal surface. The best-corrected visual acuity was less than 20/25. * Post-PSP or ocular surface reconstruction corneal neovascularization that had no associated lipid keratopathy, no corneal edema, or corneal irregularity. But the neovascularization was highly possible to cause graft rejection. * The corneal neovascularization was refractory to other medical treatment. * The patient had received PKP or other corneal surgeries mort than half a year ago and was not in the acute post-operation phase. * The patient had no active endophthalmitis, glaucoma with uncontrolled intraocular pressure, or vitreoretinal diseases. * The patient signed inform consent to have regular follow up and treatment. Exclusion Criteria: * The neovascularization had clinical improvement three months before the first injection. * The lipid keratopathy had clinical improvement three months before the first injection. * The patient that suspected to have poor visual outcome or had already been light sense negative Glaucoma patient that had uncontrolled intraocular pressure. * Poor corneal epithelialization. * Patient that had systemic disease which was not suitable for bevacizumab use. * Pregnant patient.